Generic filters
Filter by content type
Taxonomy terms

LAUL – Laurus Labs Ltd


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 7.48

Low: 5.67

High: 8.7

Total Analysts: 11

Company Profile

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, antidiabetics, anti-asthma and gastroenterology. It also develops and manufactures oral solid formulations, which provide contract research and manufacturing services (CRAMS) to other global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. The Company operates through four business units covering a range of therapeutic applications, including Generics API, which is engaged in the development, manufacture and sale of APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which is engaged in the development and manufacture of oral solid formulations; Synthesis, which is a key starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which is engaged in the recombinant products.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan